Li et al. were the first to demonstrate targeted gene correction in vivo by delivering ZFN and a partial F9 (coagulation factor IX, FIX) cDNA cassette with AAV8 to the liver of a humanized mouse model of hemophilia B (Li et al., 2011). This evidence concerns the gene F9 and hemophilia B.